GLP-1 & MetabolicPhase 3S

Retatrutide

LY3437943

Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials. The TRIUMPH-4 trial (December 2025) achieved 28.7% average weight loss (71.2 lbs from a 248.5 lb baseline) at 68 weeks with 12mg — the highest weight loss efficacy recorded for any obesity medication to date. FDA approval is anticipated in 2026–2027.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
4
Research grade
S
Community score
50

Trend index

Trackers
453

Overview

About Retatrutide

Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials. The TRIUMPH-4 trial (December 2025) achieved 28.7% average weight loss (71.2 lbs from a 248.5 lb baseline) at 68 weeks with 12mg — the highest weight loss efficacy recorded for any obesity medication to date. FDA approval is anticipated in 2026–2027.

Category
GLP-1 & Metabolic
Regulatory status
Phase 3
Also known as
LY3437943
Self-reports
125

Community

What 125 users report

125 community reports

Positive 99% · Neutral 1% · Negative 0%

Most reported benefits

Appetite
222

Most reported side effects

Nausea
3

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
5
25–50
0
50–100
0
100–200
3
200–400
6
400–600
10
600–1000
5
1000–2000
80
2000+
113

How repeat users are trending

Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.

Overall, repeat reporters leaned similar or mixed compared to their previous entry.

Median gap between entries: 51 days · Based on 45 repeat reporters

Research

Cited research (2)

PubMed

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

Rosenstock et al., 2023

Source
Wiki study page →

Help

Frequently asked

What do PeptIQ users report about Retatrutide?

This page summarizes 125 anonymized self-reports from PeptIQ users who track Retatrutide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Retatrutide?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Retatrutide safe to use?

This wiki does not assess safety or recommend use. Retatrutide is listed as Phase 3. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Retatrutide?

Research, primarily in animal models, suggests Retatrutide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Retatrutide?

Retatrutide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Retatrutide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Retatrutide?

The safety and effectiveness of Retatrutide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Retatrutide?

While there are over 200 published studies on Retatrutide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source